LMNL - Liminal enters into agreement with Kedrion to divest plasma collection business

Liminal BioSciences (LMNL) has signed a binding share purchase agreement for the sale of its plasma collection centers operated in Winnipeg, Manitoba and Amherst, New York, through its subsidiaries, Prometic Plasma Resources, and Prometic Plasma Resources ((USA)).The company will sell its collection centers to Kedrion S.p.A. for an aggregate purchase price of $17M, which Liminal will receive upon completion.Under the agreement, the parties have agreed that upon closing of the proposed sale, the company will enter into an option agreement with Kedrion for the right to acquire the remainder of its plasma-derived business.Liminal also said it will receive up to 70% of net proceeds from sale of priority review voucher for which it is potentially eligible with the possible FDA approval for Ryplazim.Ryplazim ((Plasminogen)) is an investigational drug which helps in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis.

For further details see:

Liminal enters into agreement with Kedrion to divest plasma collection business